Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; iron oxide yellow; purified talc; povidone; titanium dioxide; iron oxide red; polyvinyl alcohol; microcrystalline cellulose; macrogol 3350; iron oxide black - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 87.36 mg (equivalent: tapentadol, qty 75 mg) - tablet, film coated - excipient ingredients: macrogol 3350; polyvinyl alcohol; iron oxide red; croscarmellose sodium; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; magnesium stearate; iron oxide yellow - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, film coated - excipient ingredients: purified talc; titanium dioxide; croscarmellose sodium; polyvinyl alcohol; lactose monohydrate; macrogol 3350; microcrystalline cellulose; povidone; magnesium stearate - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmaco distribution (pty) ltd - tablet - see ingredients - tablet diazepam 10 mg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc spain - 25's blister - tablet - 5mg / tablet - central nervous system-hypnotics , anxiolytics

United States - English - NLM (National Library of Medicine)

roche laboratories inc. - diazepam (unii: q3jtx2q7tu) (diazepam - unii:q3jtx2q7tu) - diazepam 2 mg - valium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. in acute alcohol withdrawal, valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. oral valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. the effectiveness of valium in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. valium is contraindicated in patients with a known hypersensitivity to diazepam and, because of lack of sufficient clinical experience, in pediatric patients under 6 months of age. valium is also contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome. it may be used in patients with open-angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow-angle glaucoma. valium contains diazepam, a schedule iv controlled substance. valium is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse of benzodiazepines may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings: abuse, misuse, and addiction). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). valium may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses), those who have had longer durations of use (see warnings: dependence and withdrawal reactions). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue valium or reduce the dosage (see dosage and administration: discontinuation or dosage reduction of valium and warnings: dependence and withdrawal reactions). acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. more severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. protracted withdrawal symptoms may last weeks to more than 12 months. as a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. tolerance to valium may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of valium may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; aluminium magnesium silicate; lactose monohydrate; purified talc; maize starch; croscarmellose sodium; magnesium stearate - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: aluminium magnesium silicate; lactose monohydrate; croscarmellose sodium; povidone; maize starch; magnesium stearate; purified talc - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - dapoxetine hydrochloride, quantity: 33.6 mg (equivalent: dapoxetine, qty 30 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; titanium dioxide; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; iron oxide yellow; microcrystalline cellulose; hypromellose; triacetin; iron oxide black - priligy is indicated for the treatment of premature ejaculation (pe) in men 18 to 64 years of age, who have all of the following: an intravaginal ejaculatory latency time (ielt) of less than two minutes; and persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and marked personal distress or interpersonal difficulty as a consequence of pe; and poor control over ejaculation.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - sertraline hydrochloride, quantity: 112 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; sodium starch glycollate; hyprolose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - children and adolescents,sertraline generichealth is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults,sertraline generichealth is indicated for the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder.,sertraline generichealth is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse.,sertraline generichealth is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.